Clinical Trial Update: Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of denileukin diftitox (Ontak) given after autologous transplantation in multiple myeloma; the trial was terminated with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ONTAK (denileukin diftitox)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED | Results posted: 2013-12-16